Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Recognizing the value of the discovery and validation of new pharmaceutical targets would be a major step forward for pharmaceutical policy. Patent law has a significant influence on drug ...

Lydia E. Pinkham’s Vegetable Compound was one of thousands of popular and lucrative patent medicines—health concoctions dreamed up by chemists, housewives, and entrepreneurs—that took the ...

Additionally, Editas Medicine management will participate in the following upcoming investor conferences in March: To access the live webcasts of Editas Medicine’s presentations, please visit the ...

President Donald Trump’s health secretary nominee last week indicated he’d consider authorizing the government to seize the patents of high-priced medicines from manufacturers and share them ...

Clearmind Medicine Inc., a Vancouver-based biotech company specializing in psychedelic-derived therapeutics, announced the publication of a new patent by Mexico's National Patent Office.

Milestone’s NDA for CARDAMYST is currently under review at the FDA with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025. The Company continues to advance commercial preparations ...